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Background: Energy homeostasis is sustained by multiple complex pathways, and appetite 
regulation is one of them. Malnutrition such as obesity or undernutrition, which is known to 
impair individual health and lower quality of life. The association between appetite regulation 
and gastrointestinal (GI) hormones is an attractive target for therapeutic and dietary 
interventions, as well as through physical activity and exercise. Ghrelin is known to increase 
hunger, and insulin-like peptide 5 (INSL5) is a novel hormone in appetite regulation that is 
suggested to also increase hunger.   
Aim: This study set out to investigate if 20 mg marine peptide hydrolysate (MPH) per kg 
body weight would affect the secretion pattern of ghrelin and INSL5 after endurance cycling, 
as well as to explore the effect of the appetite regulating hormones following the endurance 
cycling.  
Participants and method: The study population (n=14) was composed of a moderately 
homogenous sample population of middle-aged, well-trained, healthy males recruited in July 
of 2017. Anthropometric measurements, circulating GI hormones, self-reported feeling of 
satiety and a 4-day food intake record was measured in this study.  
Results: There is significant difference in circulating ghrelin (p = 0.014) in treatment, 
compared to placebo. Additionally, there was a negative effect when adjusted for body mas 
index (p = 0.03). A positive trend in circulating INSL5 was observed, however not significant 
(p = 0.12). Correlations between ghrelin, INSL5, glucose, insulin and satiety was statistically 
significant (p < 0.05). There is a negative relationship between INSL5 and ghrelin (p < 0.01), 
and a very strong, almost linear correlation between INSL5 and insulin (r = 0.93, p < 0.01). 
The correlations also revealed that an increase in ghrelin secretion reduced satiation, while an 
increase in INSL5 increased satiation. The self-reported food intake revealed that 85 % of the 
participants did not meet the daily recommended intake (DRI) of energy and 62 % did not 
meet the DRI of protein as recommended by the Nordic Nutrition Recommendation.  
Conclusion: This study discovered that a small amount of MPH had an effect on ghrelin 
secretion, and the absence of results for the other variables may be due to a low dosage. 
Interestingly, the novel INSL5 promotes satiation and are in undiscovered way involved in 
insulin secretion.  
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Chapter 1: Introduction  
 
1.1 General background 
Energy homeostasis is the vital biological process involving food intake regulation and energy 
expenditure. When energy intake is exceeding means of energy expenditure, it is stored as 
excess energy; glycogen, triglycerides or body fat (3, 4). This is known as a positive energy 
balance. On the other hand, there occurs a negative balance when the energy intake is lower 
than the energy expenditure.  
Obesity is a polygenic disorder, and is associated with a state of low level of inflammation. 
The disorder arises through a positive energy balance over time and is commonly identified 
by excessive or abnormal accumulation of fat that could impair the health of the individual 
and is defined by a body mass index (BMI) ≥ 30 kg/m2 (5). In the later decades, incidents of 
obesity are fast growing and are doubled since 1980, reaching 600 million (5). This number is 
only expected to be continually rising unless we are able to change how we are currently 
combatting this issue. 
The increase in portion sizes and overconsumption of energy dense foods have become a 
public health concern and are possibly key factors in the increasing incidents of obesity that 
we see worldwide (6), and especially in the western world. Obesity and its comorbidities are 
one of the main health challenges the world is fighting this days. The comorbidities of 
obesity, including a variety of metabolic disorders, cardio vascular complications, 
psychosocial issues and cancer have increased the risk of mortality for the affected individual 
(7-9). To address this rising epidemic, it is important to recognise the treatment interventions 
that are available in targeting various short- and long-term mechanisms of energy homeostasis 
(10) and the effects of these treatments.  
Physical activity has a great impact on human health, and it is well established that physical 
activity has major influence on body composition and energy homeostasis (11). Physical 
inactivity, similarly to obesity, increases the risk of cardiovascular disease and stroke, type 2 
Diabetes Mellitus, some types of cancers such as breast cancer and colon cancer (12). It is 
also associated with injuries and mental health issues (13). Physical activity and exercise is 
recommended around the world as a strategy of weight loss and weight management, simply 
because it is increasing energy expenditure (14). Multiple studies have observed that exercise 
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suppress the feeling of hunger and alters secretion of appetite regulating hormones during and 
after exercise (15, 16) (also called exercise-induced anorexia (17). These responses are 
suggested to coincide with the fluctuations in gastrointestinal (GI) hormones which regulates 
appetite and energy balance due to exercise (18). By further exploring the regulation of GI 
hormones, especially ones that are involved in appetite regulation and energy homeostasis. 
This may offer a therapeutic target for obesity treatment in cooperation with exercise or in 
other ways. This will also further the understanding of obesity and the mechanisms of appetite 
and body weight regulation 
 
1.2 The Endocrine Regulation of Appetite  
Appetite and body weight control is regulated by the interactions between the GI tract, 
adipose tissue and the hypothalamus (7, 19). The hypothalamus is the main regulatory organ 
of the endocrine system in humans, and together with the brainstem receives peripheral neural 
and hormonal signalling regarding the availability of energy in the body at all time (7, 20). 
The main function of GI hormones are to optimize digestion and the absorption of nutrients in 
the gut (21). They are also involved in regulating blood glucose levels, exocrine secretion, 
growth and adipocyte function (22). The hormones which are released in the GI tract reflect 
the nutritional status on a meal to meal basis (22). 
The arcuate nucleus (ARC) in the hypothalamus plays a significant part in the gut-brain axis, 
containing orexigenic (supresses satiety) and anorexigenic (increase satiety) neurons, which is 
stimulated by short- and long-term signals as shown in Figure 1 (1). The ARC recieves 
hormonal signals from the pheripheral such as the muscle, liver and adipose tissue. 
Circulating insulin and leptin reflects the long-term availability of energy from the body’s 
stores either activating the orexigenic or anorexigenic neurons depending on the level of these 
hormones (20, 23). In contrast, short-term signals of energy availability such as peptide YY 
(PYY) and ghrelin are secreted in respons to meals  (20). Both types of signals acts on the 
neurons in the ARC either promotes (orexigenic) or inhibits (anorexigenic) appetite and 
feeding.  
Orexigenic hormones such as Ghrelin and Insulin-Like Peptide 5 (INSL5) stimulates appetite 
by expressing neuropeptide Y (NPY) and Agouti-related protein (AgRP), while anorexigenic 
hormones such as PYY and Glucagon-like peptide-1 (GLP1) inhibits appetite by expressing 
alpha-melanocyte-stimulating hormone (alpha-MSH) which are derived from cocaine- and 
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amphetamine-regulated transcript (CART) and pro-opiomelanocortin (POMC) (20). This is 
illustrated in Figure 1.  
Figure 1 The endocrine regulation of appetite. Figure from Boyle (1).  
 
1.2.1 Ghrelin 
Ghrelin is an 28 amino acid peptide most known as an appetite-regulating hormone with 
orexigenic properties (24). It is mostly produces in the stomach (25) and has since discovery 
in 1999 (24) become a significant endocrine target in obesity treatment and appetite control. 
Ghrelin is also involved with and have a regulatory role in several systems and organs in the 
body (26-28). There are two forms of Ghrelin in circulation; acylated (AG) and unacylated 
Ghrelin (UAG) (24). The human Ghrelin gene has been located at chromosome 3, locus 3p25-
26 (26, 29) containing 5 exons (24). Ghrelin is contributing to body weight regulation by 
stimulating growth hormone (GH) secretion at the pituitary in the brain (30), giving a 
reduction in energy expenditure and increase in adiposity (31, 32).  
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There are several physiological functions of Ghrelin; increasing blood glucose and decreasing 
insulin (33), reducing blood pressure (34), increasing cardiac output (35), it increases gastric 
acid secretion and gastric movement in the stomach (36). However, it is generally identified 
by its GH-stimulating action (37) as well as being fundamental in regulation of appetite, meal 
initiation and nutrient sensing (26, 27). Ghrelin is produced and secreted by ghrelineric cells 
mainly in the stomach (25), and can be found in the hypothalamus (38), pancreatic islets (39), 
heart and kidney (40).  
The pathways underlying the orexigenic effects of Ghrelin are centered around the Growth 
Hormone Secretagogue Receptor 1a (GHSR-1a), which is found to be abundantly expressed 
within the ARC of the hypothalamus (41, 42). Food intake regulates and stimulates orexigenic 
peptide release by ghrelin-containing neurons activating NPY and AgPR neurons through the 
GHSR-1a. Activation of the GHSR-1a initiates the secretion of GH, which in turn stimulate 
appetite, adiposity, blood glucose, gastric acid secretion, gastric movement, turnover of 
gastric and intestinal mucosa, stimulating cardiac output and decreasing blood pressure 
locally (26-28, 34-36). 
Ghrelin is suggested to influence blood glucose homeostasis by affecting the secretion of 
insulin and the signalling to the insulin receptor. Research is also starting to suggest that 
insulin can affect circulating ghrelin levels at some point (33, 43), however this mechanism is 
still being explored. 
 
1.2.2 Insulin-Like peptide 5   
Insulin-like peptide 5 (INSL5) is a part of the insulin/relaxing superfamily and have been 
identified as a product of the enteroendocrine L-cells in the epithelium in colon and rectum 
(44). INSL5, containing 135 amino acids, was first discovered in 1999 expressed in colon, 
rectal and uterine tissue (45). Grosse and co-workers found that INSL5 encourages feeding 
during situations of calorie restriction (46) and is only the second orexigenic GI hormone to 
be discovered after Ghrelin. It has been suggested to act on appetite and regulation of food 
intake by binding specifically to the Relaxin Family Peptide Receptor 4 (RXFP4), which is 
primarily expresses in the peripheral tissue (47, 48). 
This novel peptide have also been hypothesised in regulating metabolism via either affecting 
insulin production and glucose tolerance (49), regulating hepatic production of glucose (50), 
secretion of insulin (51) or via food-intake stimulation (46). INSL5 have been shown to be 
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regulated by available energy in the body and the gut microbiota, as well as it has been 
suggested that it may be a novel hormone in hepatic glucose production, however mild effect 
(50). Lee and co-workers suggest that INSL5 possibly acts as a sensor of energy as well as a 
modulator of glucose production during energy deprivation conditions (50). INSL5 have also 
been reported to be stimulating secretion of insulin in vivo (51), and there have been reported 
a sex-dependent variance in the circulating INSL5 in lean versus obese humans (52). The 
exact physiological function of INSL5 have not yet been defined (48). Nor have the 
orexigenic properties of this peptide been fully defined.  
 
1.3 Blood glucose homeostasis and exercise  
 The regulation of blood glucose involves maintain glucose levels in the blood at a 
constant level when facing energy intake and energy expenditure by the body. There are two 
main hormones involved in maintaining the targeted average range of blood glucose 4 – 5.5 
mmol/l (75-110 mg/100 mL); insulin and glucagon (53). Figure 2 displays the mechanisms of 
blood glucose in the body. A rise in blood glucose stimulates beta cells in the pancreas which 
increases insulin production and circulation. Glucose uptake by cells in the body, which 
decreases blood glucose to stabilize blood glucose levels, and glucose is converted in to 
glycogen and fat by the cells. A fall in blood glucose stimulates alpha cells in the pancreas, 
which increases circulating glucagon. Glucagon is then converted to glucose in muscles and 
the liver, and then released in to the blood stream to stabilize blood glucose levels.  
Preserving an adequate supply of blood glucose during exercise is crucial. During exercise, 
blood glucose levels are maintained or amplified by the regulation of glucose from the 
kidneys and liver, and from other sources of energy (54) (55). It is the autonomic nervous 
system, regulation of hormones and enzyme activity alterations that are involved in the 




Figure 2 Mechanisms of blood glucose homeostasis 
 
1.4 Proteins, satiety and weight management 
Proteins are an essential part of the human diet and are the most satiating macronutrient (56-
58). Dietary proteins are broken down in to shorter peptides and amino acids when in the 
intestine. Both peptides and amino acids have different pathways of absorption; peptides are 
being absorbed by a Na+/H+ channels, while amino acids are absorbed by specific Na+/K 
ATPase channels (59, 60). Peptides act more effectively as they are rapidly absorbed and 
accounts for greater than 60 % of the amino acids that are absorbed by the intestine (61).  
A rise in dietary protein intake have shown to have multiple positive outcomes which is 
thought to be due to the reduction in energy intake associated with an increase in satiety (56-
58), enhancing glycaemic control (62), increased thermogenesis (63) and the positive effects 
on body composition, especially muscle mass (62, 64). A high protein diet seems to be 
beneficial in weight loss and weight management, based on the associated benefits discussed 
above, together with the rise in thermogenesis and for some individuals it may also have a 
stimulatory effect on the muscle protein anabolism (10). This suggest that an increase in 
protein intake, at the expense of other macronutrient, promotes satiety and thereby facilitates 
weight loss by reduction in energy consumption (65).  
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Diets high in protein, where 18-20 percentage of total energy (E%) is dietary protein have been 
shown to effectively manage obesity due to appetite suppression (66), however the long-term 
effect of a high protein diet is still not clear (67, 68).  
 
1.4.1 Protein hydrolysates and MPH 
A hydrolysate is a product of hydrolysis, and a protein hydrolysate (PH) is a product from a 
purified source of protein (69). It is especially attractive in exercise and sports medicine as the 
consumption of protein hydrolysates allows for a more rapid absorption of amino acids and 
therefore optimizing the delivery of nutrient to muscle tissue (70). Different protein 
hydrolysates vary from each other nutritionally and due to this may cause different responses 
(71). It generally increase the absorption kinetics and digestion, as well as it induces a greater 
insulin response when consumed alone (72).  
Marine peptide hydrolysate (MPH) is assembled of approximately 95% short peptides, mainly 
dipeptides and tripeptides, which is generally largely absorbed in the mucosal cells (72). 
Marine peptides are especially favourable due to the vide spectra of bioactive properties; 
antimicrobial, antihypertensive, anticoagulant and anti-atherosclerotic, anxiolytic anti-diabetic 
and appetite suppression (73). Because of this, there are currently multiple marine peptide 
products on the market, as well as there are a few currently in clinical trials. It is a very 
attractive research field, especially with the bioactivity of the compound, the natural 
abundance and potential sustainability in production (73). MPH are through to be a very 
valuable nutrient resource for the pharmaceutical and nutraceutical industry as well as the 
food industry as a supplement that could be added into every day food items.  
Siegler and co-workers examined the effects of introducing a MPH at the same time of 
carbohydrate and whey protein on the metabolism and performance of endurance exercise in 
the form of cycling (69). They found that an addition of MPH gave a significant effect on 
exercise metabolism, however more research is needed to investigate the performance 
benefits and the mechanisms behind these results and the efficacy of adding a MPH in a 






There is an associated between appetite and secretion of GI-hormones. When treating 
overweight both diet and physical activity is important.  
The project leader assumed that there will be a bioactivity associated to the endocrine system 
with concentrations equivalent to 20 mg marine peptide hydrolysate per kg body weight.  
The hypothesis is therefore that a small amount of marine peptides will affect the secretion of 
ghrelin and INSL5 post endurance cycling.  
 
1.5.1 Aim  
I. To explore how a marine peptide hydrolysate affect GI hormone Ghrelin and 
Insulin-like peptide 5 secretion 
II. To explore the effect of these hormones following endurance cycling 
This study may contribute to better understanding appetite regulating hormones and the 
mechanism of appetite and body weight regulation. This in turn offers a potential therapeutic 













Chapter 2: Method  
 
2.1 Study Design  
This is a randomized double-blinded, placebo controlled pilot study with a crossover design 
investigating INSL5 and ghrelin secretion in plasma at time intervals until 120 minutes after 
the endurance cycling and receiving a small amount of MPH supplement. Common GI 
symptoms were assessed at the same time as INSL5 and ghrelin by a visual analogue scare 
and a categorical scale. Food intake registration was performed to investigate the diet of the 
study population.  
This study was divided in to tree phases: baseline testing, intervention day one and 
intervention day tree (crossover).  
 
2.2 Study population 
The determination of the study population was estimated based on the mean changes in mean 
blood glucose profiles of 20%, a power of 80 %, alpha of 0.05 and with a standard deviation 
(SD) of 10%. These calculations estimated that 14 participants had to partake in the study. 
Healthy male volunteers (n=14), between 40-50 years, medium trained with cycling as the 
main source of exercise, with a total amount of 8-12 hours of exercise training each week 
were recruited for this study. This recruitment approach attained optimal stability and low 
variation between the participants.  
The participant recruitment started July 2017. It was conducted by publishing an 
informational poster (Appendix 1) on social media site of local cycling clubs in Bergen, 
Norway. The inclusion and exclusion criteria (sees Chapter 2.2.1) were used in screening the 
potential candidates per email. 
 
2.2.1 Inclusion and exclusion  
The screening of potential participants was performed per email. Inclusion and exclusion 





o Signed informed Consent 
o The subject is a man between 40-50 years 
o The subject has a body mass index (BMI)  between 19–29 
o Willing to comply with all study procedures and be available for the length of the study 




o The subject has had surgery or trauma with significant blood loss or has donated blood 
within the last 3 months prior to the screening visit 
o Diabetes type 1 or 2, or persistent high blood sugar levels 
o The subject has tested positive for human immunodeficiency virus (HIV) 
o Hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (anti-HCV) 
o The subject has taken any investigational drugs within 1 month prior to screening 
o Treated with antibiotics within 3 months prior to screening (oral, parenteral or rectal), but 
not spray or ointment 
o Treated with steroids within 1 month prior to screening (including oral treatment) 
o Treated with medication that effects the intestinal function such as, H2- protonpump 
inhibitors, diuretics, antiemetics, antidepressants, antacids. 
 
2.3 Procedure 
The intervention was performed at the sports lab at the Western Norway University of 
Applied Sciences. The tree intervention phases will be described in this chapter.  
Phase one: The selected participants who was asked to partake in the study arrived for 
screening and baseline testing on a Thursday afternoon at the intervention facility. 
Participants were informed of the study aim and protocol, and signed the written consent form 
before start. The participants height were measured before body composition analysis was 
performed by using a InBody 720 (InBody) scanner. Baseline cycling test was performed and 
a lactate profile and a VO2 max test was conducted. After the physical cycling test, the 
participants received information regarding food intake registration required and a four-day 
food registration form was send to their email address. The participants was asked not to 
change their eating habits for the study period, but to adhered to some intake restrictions 
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mentioned in chapter 2.4. Participants received information regarding the symptom 
registration form so to familiarise themselves with it before the next phase.  
Phase two: Participants arrived at allocated times in the morning at the intervention facility. 
They were immediately informed of the logistics of the day. A peripheral venous catheter was 
fitted before baseline fasting blood collection was conducted (see Chapter 2.3.3 for details) 
Next, participants received breakfast (see Chapter 2.3.1) approximately one hour before 
endurance cycling starts. The exercise session started with a 20 minutes warmup at 60% VO2 
max subsequently followed 5 minutes cycling at 90% of VO2 max, before cyclin at 95% of 
VO2 max until exhaustion. The results from the cycling will not be presented as it is beyond 
the scope of this thesis. Immediately after the exercise session, blood collection started at 0 
minutes. Participants received either the test drink A or test drink B immediately after blood 
collection at 0 minutes. Blood was continuously collected at the following intervals after 
completing the exercise session; 15, 30, 60, 90 and 120 minutes. At the time intervals of 
blood collection, a symptom form was filled out, see Chapter 2.3.4 for details. The 
participants received a standardised hot meal (see Chapter 2.3.1) immediately after blood 
collection at 120 minutes. Participants rested for two hours before the next session where they 
performed an identical exercise session as described earlier. Participants did not receive any 
supplementation after this exercise session and blood collection was performed as earlier; 0, 
15, 30, 60, 90 and 120 minutes after completing the endurance cycling. 
Phase tree: Phase tree consist of the same layout as phase two, however participants received 
the reverse test drink than in phase two. If a participant received test drink A in phase two, the 
same participant received test drink B in phase tree. Figure 3 gives a detailed account of phase 








2.3.1 Standardised test day foods 
All participants received the same test meal, regardless of their individual needs. The 
breakfast was comprised of a whole wheat baguette with ham, cheese, green salad and 
peppers (from ‘Lie-Nielsen konditori’ at Kronstad, Norway). An option of 200 ml orange 
juice and 200 ml coffee or tea was given to the participants. A standardized hot meal was 
served after 2 hours rest post exercise session 1; a readymade meal beef stroganoff (Biff 
Stroganoff med ris), or a meat free option; readymade meal of cod, carrots, potato and leek 
sauce (Torsk I Purreløksaus med gulrøtter og poteter) both from Fjordland AS. Table 1 gives 
an account of the nutritional value and composition of the breakfast, as well as the hot meal of 
beef stroganoff from Fjordland AS. Aditionally is a meat free option to the hot meal which 
was added during conduction of the study. Table 1 does not include the test drink, for details 
see Chapter 2.3.2 
 





CHO, g Protein, 
g   
Fat, g  
Breakfast;       
- Bread 92.6 g 228 41.9  8  2  
- Ham (cooked) 24.9 g 26 0  4.5  0.9 
- Norwegian cheese (Norvegia)  33.3 g 117 0  9  9  
- Orange juice 200 ml 86 19.2 1.4  0.4  
Total:  150.7 g 457 kcal 61.1 g 22.9 g 12.3 g 
      
Hot meal a);      
Beef stroganoff, total:  460 g 423 kcal 59.8  26.7 g 8.3 g 
Cod, carrot, potato and leek 
sauce, total: 
550 g 330 kcal 37.4 g 30.8 g 5.5 g 
a) One of the participants turned out to be pescetarian on the day of the intervention, and received a hot 
meal containing cod instead of beef.  
Abbreviation:: CHO = carbohydrate  
 
The participants were allowed to drink up to 2.5 to 3 litres of water during the intervention.  
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2.3.2 Test drink; Marine peptide hydrolysate (MPH) or placebo  
The participants received test drink A or test drink B after completing exercise session 1 
during phase one, and the other test drink after exercise session 1 in phase three. It was self-
selected if they received test drink A or B during phase two and the other drink during phase 
three.  
The test drinks was provided by Firmenich Bjørge Biomarin AS Aalesund/Norway, ready 
with the participant ID and numbered with the letter A or B. The final mixing, incorporating 
cold water, was conducted approximately 30 minutes before exercise completion.  
The test drink was served in an opaque glass bottle. Each bottle contained a white powder of 
nutrients which was calculated of the individual participants weight. Test drink A contained a 
20 mg MPH/BW which replaced approximately 3.2% of the whey protein. The colour, taste 
and smell of the powder was disguised via use of technical ingredients such as flavouring 
agent, acidifier and natural colouring. Each glass bottle was given a natural strawberry flavour 
and a pink colour to mask the difference in flavour. Both test drinks were isocaloric and 
isonitrogenous.  
The test drinks is composed of a whey protein concentrate (WPC80 from TINE ASA, 
Bergen), vegetable fat (Medium Chained Triglycerides (MCT) fat powder, 70:30 from 
BERGAMAST) and maltodextrin from corn. The MPH powder is made from fish fillet of the 
Atlantic cod. The nutrient distribution is 12 % protein, 22 % fat and 66 % carbohydrates, 
which equals to 3,68 kcal/kg BW. The powder was mixed 1 g powder with 2 ml cold water 
approximately 30 minutes before completing the exercise.  
Test drink A: 66 % CHO, 8,8 % WPC, 3.2 % MPH and 22 % MCT.  
Test drink B: 66 % Cho, 12 % WPC, 22 % MCT.  
 
2.3.3 Blood Collection  
Acylated ghrelin (AG) is easily cleaved during sample collection and to ensure accuracy when 
measuring the concentration of AG in plasma. Aprotinin was added to EDTA tubes (Greiner 
Bio-One) prior to sample collection (26) to prevent this to happen to the samples. The plasma 
samples were used in measuring AG and INSL5. Serum gel tubes (Greiner Bio-One) were 
used in measuring blood glucose and insulin. 
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Participants were fitted with a peripheral venous catheter (infusjon cannula 18G, BD) by a 
qualified nurse on the inside of the elbow at time of arrival for phase two and three. The 
catheter was washed with 2.5 ml saline solution and a 3-way tap was established. Baseline 
(fasting) blood sample was also collected at this point. Blood sampling was then performed at 
0, 15, 30, 60 90 and 120 minutes after completing the exercise session, and again at the same 
time intervals after exercise session two (see figure 3 for details). Prior to each blood 
collection, the catheter was washed with 2.5 ml saline solution.  
 
Plasma collection 
The EDTA tubes was mixed by turning the blood 8-10 times. It was put on ice until the blood 
sample was centrifuged for 10 minutes at 1800 x g at 4C within 20 minutes of collection. 
Plasma was aliquoted into sterile cryotubes by pipetting. The cryotubes was put on ice until 
the sample collection was complete and during transport. 
 
Serum collection 
The serum gel tubes was mixed by turning before sitting in room temperature for a minimum 
of 30 minutes before centrifuging at 1800-2200 G in 10-15 minutes at room temperature. 
Serum was then removed by pipetting and aliquoted into designated sterile cryotubes. The 
cryotubes was stored on ice whilst waiting for blood sampling to be complete and during 
transport. All samples was stored at – 80 C until analysed (74).  
 
2.3.4 Symptom registration 
The participants had to answer two questionnaires during blood sampling after the exercise 
sessions. These questions were related to GI symptoms, hunger and satiety. 
The visual analogue scale (9) is a linear scale ranging from 0 till 100 mm containing the 
following questions and the range in which the participants marked this linear scale (see 
appendix 2); 
I. Do you experience pain in the middle part of the stomach? Ranging from no pain to 
very uncomfortable.  
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II. Are you nauseous? Ranging from not nauseous to very nauseous.  
III. Do you have a feeling of fullness in the stomach? Ranging from not at all to very full.  
IV. The total discomfort in the upper part of the stomach? Ranging from not at all to very 
discomforting.  
V. Are you satiated? Ranging from very hungry (0 mm) to fully satiated (100 mm) 
 
2.4 Four days diet registration 
The four day food intake registration was divided in to two parts; three days (one weekend 
day and two weekdays) between phase one and phase two, and one weekday in the washout 
period of one week before phase three.  
The participants were informed of the concept of food intake registration and the diet 
registration form during phase one. The diet registration form “Kostregistrering” from Helse 
Bergen, Haukeland Universitetssjukehus – Section of Dietetics (see Appendix 2) was used in 
the introduction/walk through as well as the food registration itself. This document was sent 
to the participants per email and was filled out electronically in a word document. A 
supplementary list of commonly forgotten items to add to the food intake registration form, as 
well as some tips for weighing the food items was given in paper form at phase one. The 
participants received contact information in case if any questions or issues arises regarding the 
food intake registration.  
During the study period there were a restriction of no more than 5 cups of coffee or tea 
allowed per day, and no alcohol consumption 48 hours prior to the visits.  
The reported food intake in the diet registration form was added to Kostholdsplanleggeren 
(The Norwegian Directorate of Health), which is a validated database for calculating 
nutrients. All food items and recipes was recorded in this nutrition analysing tool.  
 
2.4.1 Estimated Energy and Protein Requirement 
Energy expenditure (EE) was calculated through the factorial method of calculating total EE 
from Resting Energy Expenditure (REE) times a physical activity level (PAL) coefficient for 
men 31-60 years of age; REE = 0.0600 W (weight, kg)) + 1,31 H (height, m) + 0.473. The 
17 
 
PAL was set to 1.9, based on the amount of exercise the participants was conducting each 
week (8-12 hours).  
The protein requirement for the study population was set to 1.5 grams of protein per kg body 
weight (BW) per day based on the amount of exercise they do each week. 
 
2.5 Measuring Ghrelin in human plasma 
Circulating AG was measured in plasma using an Enzyme Immunoetric Assay (EIA) (Bertin 
Pharma, catalogue #30110797 (CMA05306) Lot #0117). The EIA kit is formatted with 96 
wells and gives a quantitative measure of circulating AG in plasma. It is pre-coated with AG-
specific antibodies. Sample collection is specified in chapter 2.3.3, see plasma collection of 
details. A step-by-step protocol can be found in the appendix 3.  
Plate setup contained one blank, one Non Specidic Binding (NSB) and one Quality Control 
(QC) well. Standards one through seven was run in duplicate, and standard number eight in 
single due to insufficient space on the plate. Six profiles (tree individuals) was analysed per 
plate, see appendix 4 for example of plate setup. All samples and reagents reached room 
temperature before assay start.  
Reagents and buffers were prepared according to protocol and samples were diluted 1+1. 
Samples were mixed by turning 8-10 times before pipetting out the needed amount of plasma. 
Plate preparation included rinsing each well with wash buffer before distributing samples and 
reagents in designated wells. The antibodies in the well bound to any plasma AG from the 
standard solutions and from the samples. The plate was placed on a the platform shaker 
(Heidolph Titramax 100) at room temperature for incubation for two hours. After incubation, 
the plate was washed with wash buffer to remove unbound residuals left. Acetylcholinesterase 
(AChE) conjugate was added to all wells except the blank well, before incubating for yet 2 
hours on the platform shaker. The plate is washed with wash solution to remove any excess 
reagents before adding the Ellman’s Reagent, which initiates colour developments. See Figure 
4 for step-by-step illustration. Colour is developed proportional to the amount of AG bound to 
the wells. The plate was covered with an aluminium lid and incubated on the platform shaker 
for optimal colour development. Absorbance was measured periodically at 30, 45, 60 and 90 
minutes of incubation at 405 nm (Spectra max plus, microplate spectrophotometer). After 
completion, all results was analysed to determine the time of optimal incubation, which in this 
18 
 
case was after 60 minutes of incubation. The sensitivity of the kit was not high enough in this 
EIA-kit and the results was log-log transformed to get a more complete dataset, and the 
SoftMax Pro software (from Molecular Devices) was used to log-log transform the results.   
 
Figure 4 Acylated ghrelin EIA illustration. Modified figure by (2). 
 
Abbreviations: AG = acylated ghrelin, AChE = Acetylcholinesterase 
 
2.6 Measuring INSL5 in human plasma 
Circulating INSL5 was measured in plasma, using a sandwich Enzyme-linked immunosorbent 
assay (75) (MyBioScource, catalogue #MBS944278, Lot #C1402071407). The ELISA kit is 
formatted with 96 well, and provide a quantitative measure of circulating INSL5 in plasma. 
The kit is pre-coated with INSL5-specific antibodies. The sample collection is specified in 
Chapter 2.3.3, see plasma collection for details. See appendix 5 for a step-by-step protocol. 
The plate setup contained one blank and five standards all in duplicates. Six profiles was 
analysed per plate. See appendix 6 for plate setup example. All samples and reagents reached 
room temperature before assay start.  
Reagents and buffers were prepared according to the manufacturers protocol. Samples was 
mixed by turning 8-10 times before pipetting each sample. Samples and the standards were 
distributed to the designated wells on the plate (see plate setup). The antibodies pre-coated in 
the wells bound to INSL5 from the standard solutions and the samples. This was followed by 
Horseradish Peroxidase (HRP) conjugated antibody that binds to the antigen explicitly and 
1. Antigen 
coated wells 
2. AG binds to 
the antigen  
3. AChE conjugate 
is added to bind the 
AG 





incubated for one hour at 37C. The plate was washes with wash buffer after incubation to get 
rid of any unbound reagents before adding the two substrate solutions. The substrates initiated 
a development of colour proportional to the amount of INSL5 that is bound to the antibodies 
in the well. After incubating in 15 minutes at 37C, a stop solution was added to stop the 
colour development and absorbance was measured. See Figure 5 for step-by-step illustration. 
A microplate reader (spectra max plus, microplate spectrophotometer) measured optical 
density of the wells within 10 minutes of adding stop solution at 450 nm. The results was log-
log transformed, which was one of the options in this kit.  
 
Figure 5 Insulin-like peptide 5 ELISA illustration. Modified figure by (2). 
 
Abbreviations: INSL5 = Insulin-like peptide 5, HRP = Horseradish Peroxidase.  
 
2.7 Blood glucose and Insulin measurement  
Serum glucose and insulin were analysed at the Laboratory for Clinical Biochemistry (LKB) 
at Haukeland University Hospital using standardised methods for Glucose measurement 
(http://www.analyseoversikten.no/analyse/215) and insulin 
(http://www.analyseoversikten.no/analyse/22). See the links for more details.  
“For statistic calculations, insulin values under the limit of determination (<2 mlE/L) were set 
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2.8 Ethical considerations 
This study was approved by the Western Norway Regional Committee for Medical and 
Health Research Ethics (REK 2017/56). All participants received written information 
regarding the study before committing to the study. Participants who were asked to partake in 
the study were also informed that this study is completely voluntary and if they at any time 
could withdraw from the study without giving any reasons. The participants gave their written 
consent after being fully informed of the aim and the protocol of the study (Appendix 7)  
The endurance exercise testing was performed on the cycle ergometer, and is a common 
component of exercise capacity assessment. The tests performed were strenuous, however the 
participants well-being was always being attended and testing would stop if the participants 
displayed any forms of discomfort.  
Participation was anonymous and the participants received an identification number during 
the first phase of the study. Throughout the study period and during analysing and processing 
the samples, participants stayed anonymous. The data was stored on a password protected 
research server and the data was stored on a password protected computer during analysis of 
the results. 
 
2.5 Statistics  
IBM SPSS Statistics 25 (SPSS Inc., Chicago, IL) was used to perform the statistical analyses.  
Descriptive analysis was performed to characterize the participant demographics and the diet 
registration. Results are reported as means, percent, standard deviation (SD), mean, standard 
error of mean (SEM) and 95 % confidence intervals (CI). For correlations a Pearson’s 
correlation was used.  
A mixed linear regression analysis was performed for each outcome variable (ghrelin, insulin-
like peptide 5, glucose and insulin) using SPSS, with respect to treatment, time, session, 
including adjustment for BMI. Compound symmetry correlation structure was assumed 
between measures from the same subject.  
Pearson’s and Spearman’s correlation was performed between GI hormones, and measured 
satiety by visual analogue scale.  
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GraphPad Prism (GraphPad Software, Inc., San Diego, CA) was used to measure area under 
























Chapter 3: Results  
 
3.1 Participants demographics  
Fourteen healthy men participated in the study. Mean (range of) age was 46 years (40 to 58 
years), body weight 80.1 kg (71.2 to 96.2 kg), and height 180.8 cm (176 to 192 cm). The 
mean calculated BMI (kg/m2) was 24.5 kg/m2, giving a range in BMI from 21.4 to 29.4 
kg/m2.  For detailed descriptive statistics regarding the participant demographics see Table 2 
below.  
 
Table 2 Descriptive statistics of participant demographics measured by the body composition 
analysis (n = 14).  
Characteristic Mean (SEM) Median (SD) Range (Min, Max) 
Age (years) 45 (1.42) 45 (5.3) (40, 58) 
Height (cm) 180 (1.1) 181 (4.1) (176, 192) 
Weight (kg) 80.1 (1.72) 79.8 (6.4) (71.2, 96,2) 
BMI (kg/m2) 24.5 (0.6) 24.7 (2.2) (21.4, 29.4) 
MM (kg) 37.7 (0.6) 37.8 (2.3) (33.9, 40.9) 
FM (kg) 13.5 (1.2) 12.6 (4.5) (5.8, 24.7) 
FM (%) 16.6 (1.2) 15.5 (4.4) (7.8, 25.7) 
FFM (kg) 66.6 (1.0) 66.6 (3.7) (60.4, 71.5) 
Abbreviations: SEM = standard error of mean, SD = standard deviation, BMI = body mass 
index, MM = muscle mass, FM = fat mass, FFM = fat free mass. 
 
3.2 Circulating active ghrelin post endurance cycling  
Table 3 presents the results of a linear mixed regression analysis performed for ghrelin with 
respect to the independent variables: treatment, cycling session, and time (min) including tests 
for interactions. Statistical significant differences was found between the treatments (p = 
0.014), between cycling session 1 and 2 (p < 0.001), between the time intervals of blood 
collection post cycling at cycling session 2 (p < 0.001) and for the interaction cycling session 
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1 and the time intervals (p < 0.001). There was a negative effect of endurance exercise when 
adjusted for BMI: -1.71 (estimate), 95 % CI: (-3.24, -0.19), p = 0.031.  
 
Table 3 Acylated ghrelin as function of treatment, session and time (n=13) a).  
a) Complete dataset from participant 3 is missing. b) Linear mixed regression analysis. c) Data from 7 
time points are missing total 305 samples. 
Abbreviations: CI = Confidence interval, MPH = marine peptide hydrolysate.  
 
Figure 6 show the circulating AG during session 1 compared to session 2, independent of 
treatment. A greater amount of circulating AG was measured in session 2 compared to session 
1. This difference is statistically significant (p < 0.001). 
Variable category Estimate 95% CI P-value b) 
Intercept 16.00 (11.28, 20.71) < 0.001 
Treatment   0.014 
MPH -1.85 (-3.33, -0.37)  
Placebo 0.00 (reference) . 
Cycling session  
  
< 0.001 
1 -2.68 (-6.38, 1.03) 
 




0 -5.16 (-8.87, -1.45) 
 
15 -5.80 (-9.54, -2.06) 
 
30 -3.56 (-7.26, 0.15) 
 
60 0.78 (-2.93, 4.49) 
 
90 5.18 (1.47, 8.89) 
 
120 0.00 (reference) . 
Cycling session 1 × Time, min c) 
 
< 0.001 
1 × 0 2.76 (-2.39, 7.92) 
 
1 × 15 1.24 (-3.96, 6.45) 
 
1 × 30 -0.16 (-5.34, 5.02) 
 
1 × 60 -4.68 (-9.83, 0.48) 
 
1 × 90 -6.40 (-10.58, -0.22) 
 
1 × 120 0.00 (reference) . 
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Figure 6 Circulating acylated ghrelin measured at time points in cycling session 1 and 
session 2 (n=13, p < 0.001).   
 
Circulating AG was also calculated by an area under the curve (AUC) analysis which is 
shown in Figure 7, and Table 4. Figure 7A shows at what time the participants received MPH 
or placebo. The greatest measured circulating ghrelin in session 1 is measured at fasting (time 
point – 60, Figure 7A and Table 4), which was measured to be 17.96 pg/mL for MPH and 
13.28 pg/mL for placebo. In session 2, the greatest measured circulating ghrelin is measured 
at 90 minutes after completing the endurance cycling and was measured to be 18.4 pg/mL for 
MPH and 22.09 pg/mL for placebo (figure 7B and Table 4).   
 
A: cycling session 1, B: cycling session 2. P < 0.001.  
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Figure 7 Circulating acylated ghrelin as function of treatment (n = 13).  
 
Table 4 Acylated Ghrelin measured by area under the curve (n=13) a). 
 Session 1 b) Session 2 c) 
Parameters MPH Placebo MPH Placebo 
Total Area 1946 1984 1624 1951 
SEM 613.1 512.2 382.1 596.9 
95 % CI (744.1, 3147) (979.7, 2988) (874.9, 2373) (781.5, 3121) 
First X -60 -60 0 0 
Last X 120 120 120 120 
Peak X -60 -60 90 90 
Peak Y 17.96 13.28 18.4 22.09 
a) Complete dataset missing for one participant. b) Data from 3 time points are missing, total 166 
samples. c) Data from 4 time points are missing, total 152 samples. 
Abbreviations: MPH = marine peptide hydrolysate, SEM = Standard Error of Mean, CI = Confidence 
interval. 
 
Figure 7A display a great drop in circulating ghrelin between fasting values and the acutely 
effect of MPH or placebo 15 minutes after completing the exercise session and receiving the 
test drink. To compare this drop in ghrelin, a paired-samples t-test was conducted. There was 
not a significant difference in the scores for MPH (mean = 10.45, SD = 13.85) and placebo 
(mean = 4.48, SD = 5.78), t (11) = 2.09, p = 0.061. A non-parametric Wilcoxon Signed Ranks 
Test (Z) was also performed (Z = - 1.804, p = 0.077). The results from both tests suggest that 
treatment does not have an effect on the reduction in circulating ghrelin between fasting 
values and 15 minutes after exercise session ended and receiving the test drink. Treatment 






3.3 Insulin-Like Peptide 5 measurement  
Table 5 display the results of a linear mixed regression analysis performed for INSL5 with 
respect to the independent variables: treatment, cycling session, and time (min including tests 
for interactions. There was not found a statistical difference between treatment (p = 0.121), 
however a statistical significant was founf between cyclin session 1 and 2 (p < 0.001), 
between the time intervals of blood collection post cycing session 2 (p < 0.001) and for the 
interaction between cycling session 1 and the time intervals (p < 0.001). There was a non 
significant positive effect of endurance exercise when adjusted for BMI: 0.82 (estimate), 95 % 
CI: (-1.78, 3.43), p = 0.505.  
 
Table 5 Insulin-like peptide 5 as function of treatment, session and time (n=14).  
Variable category Estimate 95% CI P-value b) 
Intercept 5.58 (-4.89, 16.05) < 0.001 
Treatment   0.121 
MPH 3.88 (-1.04, 8.81)  
Placebo 0.00 (reference) . 
Cycling session  
  
< 0.001 
1 10.23 (-2.26, 22.73) 
 
2 0.00 (reference) . 
Time, min a) 
  
< 0.001 
0 13.99 (1.49, 26.49) 
 
15 3.54 (-8.95, 16,04) 
 
30 0.93 (-11.57, 13.42) 
 
60 0.19 (-12.30, 12.69) 
 
90 0.40 (-12.10, 12.89) 
 
120 0.00 (reference) . 
Cycling session 1 × Time, min 
 
< 0.001 
1 × 0 - 2.13 (-19.44, 15.19) 
 
1 × 15 8.83 (-8.48, 26.15) 
 
1 × 30 65.13 (47.82, 82.45) 
 
1 × 60 71.91 (54.59, 89.22) 
 
1 × 90 24.64 (7.32, 41.95) 
 
1 × 120 0 (reference) . 
a) Data from 4 time points are missing total 346 samples.  
Abbreviations: CI = Confidence interval, MPH = marine peptide hydrolysate. 
 
Figure 8 display the circulating INSL5 after exercise session 1 and 2, independently of 
treatment. A greater amount of circulating INSL5 was measured during the first session 
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compared to the latter. This difference in circulating INSL5 is statistically significant (p < 
0.001), as measured by the mixed model.  
 
 
Figure 8 Circulating insulin-like peptide 5 measured at time points in cycling session 1 and 
session 2 (n=14, p < 0.001). 
 
Circulating INSL5 calculated by AUC analysis is shown in Figure 9 and Table 6. Figure 9A 
show at what time the participants received MPH or placebo. The greatest concentration of 
INSL5 was measured at 60 minutes after completing exercise session 1. Mean INSL5 
concentration reached 92.45 ng/mL after receiving the MPH and 87.27 ng/mL after receiving 
the placebo (Figure 9A and Table 6). The greatest consentration after session 2 was measured 
at 0 minues, emediately after completing the exercise session. The mean INSL5 consentration 
was 25.88 ng/mL after rcieving MPH and 17.15 ng/mL after receiving placebo (figure 9B and 





A: cycling session 1, B: cycling session 2. P = 0.121. 
Figure 9 Circulating insulin-like peptide 5 as function of treatment.  
 
Table 6 Insulin-like peptide 5 measured by area under the curve analysis (n = 14). 
 Session 1 a) Session 2 b) 
Parameters MPH Placebo MPH Placebo 
Total Area 8386 7594 1199 981,6 
SEM 476 412.5 66.16 49.1 
95 % CI 7453 to 9319 6786 to 8403 1069 to 1328 885,3 to 1078 
First X -60 -60 0 0 
Last X 120 120 120 120 
Peak X 60 60 0 0 
Peak Y 9245 87.27 25.88 17.15 
a) Data from 2 time points are missing, total 194 samples. b) Data from 2 time points are missing, total 
166 samples). 





3.4 Glucose measurement 
Table 7 present the results of a linear mixed regression analysis performed for ghrelin with 
respect to the independent variables: treatment, cyclin session, and time (min) including tests 
for interactions. Statistical significant difference was not found between treatment (p = 
0.190), however there was a statistical significant difference between cycling session 1 and 2 
(p < 0.001), between the time intervals of blood collection post cycling at cycling session 2 (p 
< 0.001) and for the interaction cycling session 1 and the time intervals (p < 0.001). There 
was a non-significant negative effect of endurance exercise when adjusting for BMI: -0.10 
(estimate), 95 % CI: (-0.22, 0-02), p =0.092.  
 
Table 7 Blood glucose as function of treatment, session and time (n = 14).  
Variable category Estimate 95% CI P-value a) 
Intercept 4.93 (4.50, 5.37) < 0.001 
Treatment   0.190 
MPH 0.13 (-0.06, 0.32)  
Placebo 0.00 (reference) . 
Cycling session  
  
< 0.001 
1 -0.99 (-1.47, -0.51) 
 
2 0.00 (reference) . 
Time, min b) 
  
< 0.001 
0 1.46 (0.98, 1.94) 
 
15 0.24 (-0.24, 0.72) 
 
30 -0.07 (-0.55, 0.41) 
 
60 -0.06 (-0.54, 0.42) 
 
90 -0.03 (-0.51, 0.45) 
 
120 0.00 (reference) . 
Cycling session × Time, min 
 
< 0.001 
1 × 0 2.23 (1.56, 2.90) 
 
1 × 15 2.49 (1.83, 3.16) 
 
1 × 30 3.13 (2.46, 3.80) 
 
1 × 60 1.68 (1.01, 2.35) 
 
1 × 90 0.31 (-0.35, 0.98) 
 
1 × 120 0.00 (reference) . 
a) Linear mixed regression analysis. b) Data from 3 time points are missing, total 347 samples.  





Figure 10 show blood glucose levels during session 1 compared to session 2, independent of 
treatment. The difference in blood glucose levels are statistically significant between sessions 
(p < 0.001), as measured by the mixed model.  
 
Figure 10 Circulating blood glucose measured at time points in cycling session 1 and session 
2 (n=14, p < 0.001).  
 
Circulating blood glucose was also calculated by an AUC analysis as shown in Figure 11 and 
Table 8. Figure 11A show the time participants received MPH or placebo. The greatest 
measured circulating glucose in session 1 was 7.85 mmol/L for MPH and 7.543 mmol/L for 
placebo at 0 minutes, immediately after the exercise session (Figure 11A and Table 8). The 
greatest measured circulating blood glucose in session 2 was measured to be 6.593 mmol/L 
for MPH and 6.321 mmol/L for placebo which was measured again at 0 minutes (Figure 11B 





 A: cycling session 1, B: cycling session 2. P = 0.190 
Figure 11 Area under the curve analysis of Glucose as function of treatment (n = 14).  
 
Table 8 Blood glucose measured by area under the curve analysis (n = 14). 
 Session 1 Session 2 a) 
Parameters MPH Placebo MPH Placebo 
Total Area 1071 1050 611,3 606,6 
SEM 71.49 66.01 15.41 17.98 
95 % CI 930,8 to 1211 920,7 to 1179 581,1 to 641,5 571,4 to 641,8 
First X -60 -60 0 0 
Last X 120 120 120 120 
Peak X 0 0 0 0 
Peak Y 7.85 7.543 6.593 6.321 
a) Data from 3 participants are missing, total 165 samples. 







3.5 Insulin measurement 
Table 9 display the results of a linear mixed regression analysis performed for insulin with 
respect to the independent variables: treatment, cycling session, and time (min) including tests 
for interactionss. No statistical significant difference was found in treatment (p = 0.572), 
however there was a statistical significant difference between cycling session 1 and 2 (p < 
0.001), between the time intervals of blood collection post cycling at cycling session 2 (p < 
0.001) and for the interaction cycling session 1 and the time intervals (p < 0.001). There was a 
non-significant positive effect of endurance exercise when adjustment for BMI was made: 
1.05 (estimate), 95 % CI: (-0.27, 2.38), p = 0.109.  
 
Table 9 Serum Insulin as function of treatment), session and time (n = 14) a).  
Variable category  Estimate 95% CI P-value b) 
Intercept 3.44 (-2.12, 9.00) < 0.001 
Treatment   0.572 
MPH 0.76 (-1.87, 3.39)  




1 9.09 (2.48, 15.71) 
 
2 0.00  (reference) . 
Time, min c) 
  
< 0.001 
0 11.04 (4.42, 17.65) 
 
15 5.08 (-1.54, 11.70) 
 
30 2.69 (-3.92, 9.31) 
 
60 0.92 (-5.70, 7.54) 
 
90 0.62 (-5.99, 7.24) 
 
120 0 (reference) . 




1 × 0 -5.78 (-15.00, 3.44) 
 
1 × 15 0.20 (-9.02, 9.42) 
 
1 × 30 28.36 (19.14, 37.58) 
 
1 × 60 43.76 (34.54, 52.98) 
 
1 × 90 15.03 (5.81, 24,25) 
 
1 × 120 0 (reference) . 
a) Where serum insulin < 2 it was set to 1.9 mlE/L (37 samples). b) Linear mixed regression analysis.  
c) Data from 4 time points are missing, total 332 samples.  




Figure 12 display serum insulin during session 1 compared to session 2, independent of 
treatment. A greater amount of serum insulin was measured in session 1 compared to session 
2. The difference is statisically significant (p < 0.001).  
 
Figure 12 Serum insulin measured at time points in cycling session 1 and session 2 (n =14, p 
< 0.001). 
 
Serum insulin was also calculated by an AUC analysis which is shown in Figure 13 and Table 
10. Figure 13A show at what time the participant received MPH or placebo. The greatest 
measured serum insulin in session 1 was at 60 minutes and was 55.44 mlE/L after MPH and 
59.76 mlE/L after placebo (Figure 13A and Table 10). In session 2, the greatest measured 
serum insulin was at 0 minutes, immediately after the exercise, and was measured to be 16.39 





A: cycling session 1, B: cycling session 2. P = 0.572 
Figure 13 Circulating insulin as function of treatment.  
 
Table 10 Circulating insulin measured by area under the curve analysis (n =14). 
 Session 1 a) Session 2 b) 
Parameters MPH Placebo MPH Placebo 
Total Area 4884 4844 784,6 669,6 
SEM 792.8 923.9 169.1 142.4 
95 % CI 3330 to 6437 3033 to 6655 453,2 to 1116 390,4 to 948,7 
First X -60 -60 0 0 
Last X 120 120 120 120 
Peak X 60 60 0 0 
Peak Y 55.44 59.76 16.39 13.32 
a) Data from 1 time point is missing, total 195 samples. b) Data from 3 time points are missing, 






3.6 Association between GI hormones, and satiety 
Table 11 displays a total summary of all correlations between the variables ghrelin, INSL5, 
glucose, insulin, and satiety measure by the Visual Analogue Scale (9) questionnaire. A 
Pearson’s correlation coefficient (r) was calculated to evaluate the relationship between the 
circulating GI hormone values with glucose, insulin in the blood and satiety. A nonparametric 
Spearman’s rank-order correlation () was also calculated. Further details are shown in the 
following chapters.  
 
Table 11 Summary of correlations a) between GI hormones and satiety. 
 Ghrelin INSL5 Glucose Insulin Satiety b) 
Ghrelin 1 r = - 0.286 r = - 0.188 r = - 0.063 c) r = - 0.472 
INSL5  = - 0.500 1 r = 0.376 r = 0.928 r = - 0.282 
Glucose  = - 0.212  = 0.465 1 x x 
Insulin  = - 0.115  = 0.927 x 1 x 
Satiety b)  = - 0.503  = 0.233 x x 1 
a) Association between variables as analysed by Pearson’s correlation coefficient and Spearman’s 
rank-order correlation. b) Satiety as measured by VAS questionnaire. All correlations are significant (p 
< 0.05) except c).  
Abbreviations: INSL5 = Insulin-Like Peptide 5. 
 
The correlations between glucose and insulin, glucose and VAS, and insulin and VAS is 
beyond the scope of this thesis and will not be discussed further.  
 
3.6.1 Association between insulin-like peptide 5 and ghrelin   
The results from the correlation analysis showed a significant negative correlation between 
circulating INSL5 and ghrelin in the blood: r = - 0.286, n = 304, p < 0.001. These results are 
summarized in Figure 14A. A non-parametric correlation was performed and this analysis 
show a much stronger correlation using a non-parametric correlation coefficient ( = - 0.500, 
p < 0.001). A non-linear monotone relationship between ghrelin and INSL5, which are 
assumed to fit the data better, is displayed in Figure 14B. The negative correlation observed 
between these GI hormones suggest a novel purpose of INSL5. An increase in circulating 




A: Linear relationship. B: Non-linear monotone relationship. P < 0.001 
 
Figure 14 Correlation between insulin-like peptide 5 and ghrelin as function of treatment (n 
= 304). 
 
3.6.2 Correlation between insulin-like peptide 5 and insulin    
The results from the correlation analysis showed a very strong positive correlation between 
circulating INSL5 and insulin in the blood: r = 0.928, n = 332, p  < 0.001. These results are 
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summarized in Figure 15. A non-parametric correlation was also performed,  = 0.927, p < 
0.001. These results suggest that there is almost a linear relationship between INSL5 and 
insulin. This strong positive correlation showed that an increase in INSL5 are followed by an 
increase in serum insulin.  
 
 
Figure 15 Correlation between insulin-like peptide 5 and insulin as function of treatment (n 
=332, n < 0.001).  
 
3.6.3 Correlation between insulin-like peptide 5 and glucose   
The results from the correlation analysis reviled a significant positive correlation between 
circulating INSL5 and blood glucose: r = 0.376, n = 332, p < 0.001. Figure 16 summarizes 
these results. A non-parametric correlation was performed:  = 0.465, p < 0.001. This positive 






Figure 16 Correlation between insulin-like peptide 5 and glucose as function of treatment (n 
= 332, p < 0.001). 
 
3.6.4 Correlation between ghrelin and glucose   
The results from this correlation analysis have reviled a significant negative correlation 
between ghrelin and blood glucose: = -0.188, n = 303, p =  0.001. These results can be seen in 
Figure 17. A non-parametric correlation was performed:  = - 0.212, p < 0.001. This negative 




Figure 17 Correlation between ghrelin and glucose as function of treatment (n =303, p < 
0.001). 
 
3.6.5 Correlation between Ghrelin and Insulin 
The results from the correlation analysys did not reviel a significant relationship between 
circulating ghrein and serum inuslin: r = - 0.063, n = 303, p = 0.274, which are summarized in 
Figure 18. A non-parametric correlation was also performed:  = - 0.115, p = 0.045, where 
the p-value revealed this correlation to be significant. These results show a weak negative 
correlation between circulating ghrelin and serum insulin.  
 
 
Figure 18 Correlation between ghrelin and insulin as function of treatment (n =303, p = 
0.274). 
 
3.7 Symptom registration  
A VAS questionnaire was used to report common GI symptoms related to ingestion after 
receiving the test drink, after the endurance exercise at times of blood collection in session 1 
and session 2. Due to administrative issues, only 43 % of the participants completed the 
questionnaire. Symptom I through IV (see chapter 2.3.4 for details), was equal to zero and 
will not be reported nor discussed in this thesis. The reported feeling of satiation, ranging 
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from ‘very hungry’ to ‘fully satiated’ measures satiation over time. Correlation analysis 
between INSL5 and satiety, ghrelin and satiety will be reported in the following chapters.  
 
3.7.1 Association between circulating ghrelin and satiety 
The results from the correlation analysis reviled a significant negative correlation between 
circulating ghrelin and satiety as measured by VAS: r = - 0.472, n = 140, p < 0.001, which are 
summarized in Figure 19. A non-parametric correlation reviled  = - 0.503, p < 0.001. These 
results shows that the greatest circulating ghrelin levels occur when in the state of ‘very 
hungry’ and satiation gives a rise in circulating ghrelin. This supports the research of ghrelin 




Figure 19 Correlations analysis of ghrelin and satiety (n = 140, p < 0.001).  
 
3.7.2 Association between circulating INSL5 and satiety  
The results from the correlation analysis showed a significant positive correlation between 
circulating INSL5 and satiety as measured by VAS: r = 0.282, n = 140, p = 0.001. These 
results are summarized in Figure 20. A non-parametric correlation revealed:  = 0.233, p = 





Figure 20 Correlations analysis of insulin-like peptide 5 and satiety measured by VAS as 
function of treatment (n=140, p < 0.001).  
 
These results support previous findings in this study, where ghrelin and INSL5 seem to have 
opposite effect on appetite regulation and satiety.  
 
3.7 Self-reported food intake through 4-day food registration 
Self-reported food intake registration was performed to get a representative image of the diet 
of the study population. There was a 93 % compliance in the food intake record, and 
participant 12 was excluded from all analysis. For detailed descriptive statistics regarding the 
mean reported intake, see table 12 bellow.  
The individual mean average of reported nutrient intake, compared to the daily recommended 
intake (DRI) of the Nordic Nutrition Recommendation (NNR) was calculated (See Appendix 
9). The mean nutrient values is assumed to be representable of the diet of the study 
population. Based on the NNR, 85 % of the study population did not meet the DRI of energy, 
62 % did not meet the DRI of carbohydrates and protein, and 54 % did not meet the DRI of 






Table 12 Reported mean nutrient intake (n = 13) a).  
 Parameters Mean (SEM) Median (SD) Range (Min, Max) 
Energy (Kcal) 2889.9 (164.0) 2946.5 (591.3) (2051.0, 3952.2) 
Fat (g) 113.34 (8.61) 103.40 (31.06) (70.50, 168.38) 
CHO (g) 359.73 (24.67) 332.52 (88.94) (243.17, 505.83) 
Fibre (g) 27.23 (2.34) 25.80 (8.44) (15.04, 42.70) 
Protein (g) 117.21 (6.34) 112.40 (22.85) (90.08, 159.20) 
Vit. D (µg) 11.78 (2.18) 7.00 (7.85) (3.33, 24.35) 
Thiamin (76) 2.15 (0.29) 1.83 (1.07) (0.57, 4.01) 
Niacin (76) 19.26 (2.19) 18.75 (7.91) (5.05, 33.95) 
Vit. B12 (µg) 6.13 (0.86) 5.25 (3.10) (1.85, 12.90) 
Vit. C (76) 97.35 (16.40) 79.50 (59.12) (21.50, 196.75) 
a) One participants did not hand in the food registration form and three participants reported their food 
intake for two days.  
Abbreviations: SEM = standard error of mean, SD = standard deviation, CHO = carbohydrate, vit D = 













Chapter 4: Discussion  
In this study, the effect of a small amount of MPH on secretion of ghrelin, INSL5, glucose 
and insulin was investigated in healthy males post endurance cycling. The main findings was 
that MPH supplementation had a significant effect on circulating ghrelin, however not on 
INSL5, glucose and insulin. There was a difference, although not significant effect of a MPH 
supplement on circulating INSL5 after endurance cycling. Exercise have been established in 
supressing ghrelin, and a MPH supplement showed a further suppression of ghrelin secretion 
after endurance cycling. There were observed a tendency of increased INSL5 secretion after 
endurance cycling in MPH compared to placebo, however this was not significant. All result 
and the methodology are discussed in this chapter.  
 
4.1 Discussion of results 
The research field of appetite regulating hormones is expanding and the underlying 
mechanisms for all known hormones are not yet fully understood, especially INSL5. The aim 
of this study is to explore how MPH affect the GI hormone ghrelin and INSL5 secretion, and 
subsequently, appetite regulation. In addition, if the physical activity would influence the 
hormone secretion. The results from this study show that a small amount of MPH 
supplementation after endurance cycling gives a significant effect on circulating ghrelin 
secretion, not INSL5. Correlations were observed between hormone secretion, glucose and 
insulin. There was a negative correlation between ghrelin and INSL5, however there was a 
strong positive correlation between INSL5 and insulin.  
  
4.1.1 Acylated ghrelin secretion post endurance cycling 
A significant negative treatment effect was found in circulating acylated ghrelin, however 
independently of cycling sessions and time. This novel result suggest that the MPH 
supplement reduces circulating acylated ghrelin after endurance exercise. When adjusting for 
BMI, a negative effect was observed to be significant. A mixed model analysis revealed that 
there are statistical significance in circulating ghrelin between exercise sessions, time points 
of blood collection and between the exercise session and the time points. A potential long-
term effect was observed after exercise session two, where ghrelin was consistently lower 
than placebo, except at 0 and 15 minutes after completing the exercise.  
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A negative correlation was observed between acylated ghrelin (AG) and the following 
parameters; INSL5, glucose and insulin. These results supports ghrelin as an orexigenic 
hormone. However, surprisingly there was a negative correlation between AG and INSL5. 
Grosse and co-workers found a significant reduction in INSL5 after feeding, and INSL5 
administration stimulated food intake in mice. INSL5 administration stimulated food intake. 
They proposed that INSL5 were to join ghrelin as an orexigenic hormones in suppressing 
satiety (46).  
The significant negative effect of adjusting for BMI is contradicting the general understanding 
of BMIs implications on ghrelin secretion. Several studies have shown that BMI is positively 
correlated to circulating ghrelin (33). A possible explanation of these contradicting results 
may be that the population in this study is over the average fit, and the level of fitness affects 
ghrelin secretion in some way. Another explanation may be the exercise or the type of 
exercise. A prolonged reduction in ghrelin secretion have been reported after exercise (77). 
Exercise intensity have also been found to further suppress ghrelin secretion, where high 
intensity training is most effective (18).   
 
4.1.2 INSL5 secretion pattern post endurance cycling 
No significant effect of treatment was observed, nor when adjusting for BMI. The linear 
mixed regression analysis displayed the statistical significance in circulating INSL5 between 
exercise sessions, time points of blood sampling and between the exercise session and the 
time points.  
Although not significant, and a positive effect of MPH on INSL5 secretion. As mentioned, 
there was observed a negative correlation between circulating AG and INSL5, and 
additionally there was a positive correlation between INSL5 and glucose. Most surprising, 
there was a very strong positive, almost linear, correlation between INSL5 and insulin. INSL5 
have been identified to be produced in the specialized enteroendocrine L-cells in the colon 
mainly (46), whilst insulin is produced in beta-cells in the pancreas (78). At this point in time, 
the relationship between INSL5 and insulin is not apparent and need to be further researched.  
The absence of results for the majority of the variables can be explained by the low dosage, 
and that 20 mg per kg/body weight is not sufficient to get a significant effect.  However, these 
results together with the negative correlation between ghrelin and INSL5 are suggesting that 
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INSL5, in contrast to what is previously believed, have an anorexigenic effect in appetite 
regulation and stimulates satiety, not hunger. 
 
4.1.3 Blood glucose and insulin secretion post endurance cycling 
There was no significant effect of treatment on either glucose or insulin secretion, nor when 
adjustments for BMI was conducted. These results will not be discussed further as it is 
beyond the scope of this thesis. 
 
4.1.4 Symptom registration  
43 % of the participants fully completed the VAS questionnaire due to administrative issues. 
The results are therefore only reporting trends that may be expected to occur. The VAS 
ranged from ‘very hungry’ to ‘fully satiated’, giving a representative measure of satiety at the 
time point of blood collection, which allows us to measure satiation up till 120 minutes post 
endurance cycling. These results were expected to negatively correlate with circulating 
ghrelin and INSL5 based on the orexigenic effect on appetite regulating. The participants 
were feeling more hungry after session 2 than session 1. 
The results showed a negative correlation between circulating ghrelin and satiety measured by 
VAS, which supports the orexigenic effect of ghrelin (26). However, the correlation between 
INSL5 and satiety was found to be positive. These result are further supporting previously 
reported results, indicating INSL5 as an anorexigenic hormone.  
 
4.1.5 Reported dietary intake  
Results reviled that 85% of the participants did not meet their daily required energy intake 
which was calculated to fit the activity level of the study population. This can affect the 
successive results regarding macro- and micronutrients. 62 % of the study population are 
under the daily recommendations of carbohydrates, as well as protein intake. Results also 
reviled that 54% did not meet the daily requirement in vitamin D. Based on these results, the 
study population should increase their energy, carbohydrate and protein intake to not be in an 
energy deficit. Protein intake will be discussed further in Chapter 4.2.5. 
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Vitamin B is very important in exercise as it is involved in making red blood cells, the 
breakdown of protein and carbohydrates (glucose and glycogen) and in the rebuilding and the 
repair of tissue in the body. Low levels of vitamin B have a negative effect on performance as 
it reduced ATP production and oxygen delivery during exercise (79). 70 % of participants 
reached the DRI of thiamin, 62 % reached the DRI of niacin, and only 7 % did not reach the 
DRI of vitamin B12. Based on these result, the study population should increase their intake 
of thiamin and niacin to optimize performance in exercise. 
 
4.2 Discussion of the methodology  
In this randomized, double-blinded, placebo controlled crossover study, the following 
parameters was measures; anthropometrics, GI hormone ghrelin and INSL5, food intake and 
measurement of satiety after exercise and receiving a test drink. The strengths and limitations 
of the method and materials used in this study will be discussed.  
 
4.2.1 Study population and study design 
In total 14 participants contributed in the study. The participants was recruited via the social 
media site of local cycling clubs in Bergen. During the start-up period after the recruitment, a 
couple of participants withdraw from the study and changes was made to the inclusion criteria 
in relation to age and the age limit was extended to 58 years of age.  
One of the limitations of this study is that it is a small study population because it is a pilot 
study. Because of this, only men was included to achieve the greatest possible degree of 
unambiguous results. The sample was composed of middle-aged, well-trained, healthy males. 
Therefore, this study is somewhat one-sided as there is reasonable cause to believe that results 
can alter when women are included or in a different age group. Thus, the findings might not 
be generalized.  
Participants decided themselves on receiving treatment A or treatment B in phase two and in 
phase three receives the other treatment option. The treatment and placebo was prepared at the 
manufacturer in opaque glass flasks with white powder. Colour, taste and smell was masque. 
A randomized, double-blind, placebo-controlled, crossover design is considered a desirable 
study design. A great benefit of a crossover design is that group A and B, in this case 
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treatment A and B, is compared with them-selves in a self-paired way. Because participants 
are their own controls and is compared against themselves, this is beneficial as it ensures for a 
greater biological homogeneousness in the samples. The was-out period was set to 7 days in 
this study based on animal-studies related to the nitrogenbalance (protein balance), that 4 days 
is required to adapt to a new diet. Ever though the need for a wash-out period between phases 
in the study is a liability, it was chosen to be 7 days to make sure that alteration in the diet in 
phase 2 were not affecting the diet in the next phase.  
Another limitation of the study design is that with the crossover design, are assuming that 
there are a treatment effect of phase two have no remaining effect on the treatment effect of 
phase three. We also assume that participants health and stress level remains unchanged 
during phase two and three.  
  
4.2.2 Anthropometric measurements  
The anthropometric measurements was standardized by using exactly the same height 
measurer and body composition analyser for all participants.  
 
4.2.3 GI hormone measurements  
Blood samples was collected by a standardized method to insure accuracy and to get 
sufficient amount of blood. Glucose and insulin was measured at the Laboratory of Clinical 
Biochemistry (LKB) using a standardized method which is insuring high accuracy. Ghrelin 
and INSL5 measurement were performed in a clinical laboratory at University of Bergen with 
commercial EIA and ELISA kits respectively.  
There are a big difference in fasting values, especially in ghrelin, independently of treatment. 
This can be caused my multiple individual factors; hours of sleep (80) prior to the 
intervention, type and amount of food consumed (81, 82) the previous day, how long the 
participants were awake in the morning before arriving (83) as they received individual times 
of arrival (every hour from 8:00 a.m. till 10:00 a.m.), general stress levels and the level of 
stress which arises whilst getting to the intervention location in the morning (drive, public 
transport, traffic jam etc.) (84, 85). These are all factors that may affect levels of ghrelin, and 
any test done compared to fasting values will be limited due to the variation in values.  
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Because there are no standardised method of measuring ghrelin or INSL5, an exact 
immunoreactivity for the respective ELISA needs to be furthers characterised. Gröschl and 
co-workers conducted and evaluation of the comparability of commercial ghrelin assays. 
When two different ghrelin kits were compared, it was found that the difference in the 
standard peptide used let to a dramatic difference in levels of ghrelin measured in the assay 
(86). It is therefore possible that these result are not comparable with other measured results 
of ghrelin or INSL5 by other researchers using kits with different immunoreactivity and from 
different manufacturers.   
In this study, some of the values of GI hormones was missing, and the data set for participant 
12 was excluded from the AG measurement due to technical difficulties. This is a limitation, 
and if these values were not missing or excluded, it may have affected the results of GI 
hormones and satiety. Potentially it could help better understand AG and INSL5 secretion 
after endurance exercise.  
 
4.2.4 Symptom registration  
The result of satiety measured at time points of blood collection give a representative measure 
of satiation during the 2-hour period after the endurance exercise. 
There were observed individual differences in the VAS questionnaire results. This could be 
due to that some of the participants are habitual breakfast eaters, and are used to eating a 
larger breakfast meal, therefore scoring lower on the VAS. Others that are not habitual 
breakfast eaters will score higher on the VAS questionnaire, which is a limitation. To adjust 
for this, one can ask the participants if they are habitual breakfast eaters.  
 
4.2.5 Food intake records 
Four day diet registration was performed using a standardized diet registration form from 
‘Helse Bergen, Haukeland Universitetssjukehus – section of dietetics’. When the study started 
it was decided that a two-day diet registration was sufficient, however this was changed to 
four days to give a better reference of the average nutrient intake of the study population and 
to reflect that this is a master’s thesis in dietetics. This means however that the first three 
participants only have a two-day food registration, one day before phase two and one in-
between phase two and three. After the change was made, participants was asked to do three 
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day food records before phase two and record one day in-between phase two and three. 93 % 
of the participants complied.  
One major limitation of a food intake record is that participants themselves report their intake. 
Humans, for different reasons are not capable of precisely accounting for what they have 
eaten. A meth analysis found that the participants consequently had healthies eating habits 
during a period of keeping a food record (87, 88). Due to subjectivity we are not able to 
confidently validate the results from a food intake records because it a source of systematic 
bias (89, 90). Because diets can change over time, a food record such as this is exposed to 
random errors because it only record the diet for 4 days.  The greatest concerns are 
nonetheless systematic errors such as under- and over reporting which is suggest to be ± 20 % 
(88). Yang and co-workers found that when mean daily nutrient intake was estimates, a food 
record showed that the intake of fat, fibre, vitamin E, B6, A and β-carotene and sodium when 
compared to reports intake by a food frequency questionnaire (91). 
To improve compliance, communication with the participants could improve throughout the 
intervention, and this may lead to a low threshold for asking questions if in doubt. An option 
to complete and submit the food record form online or in a customized app on a smartphone at 
the end of the day may make it easier to log food items at work or on the go when not in the 
comfort of their own home. It would then be easy to monitor, and maybe ask questions when 
something is not clear. This method of dietary assessment is more applicable for people who 
frequently cook meals at home, and it is not suitable for individuals who are frequently eating 
outside their home (92).  
One limitation in regards to the process of adding the food items and recipes in the nutrient 
analysation program, was that the program did not include several food items and these had to 
be recorded manually. Where the product declaration from the manufacturer was available, it 
was added, however not all micronutrients was available in that situation. This is therefore 
likely to affect the reported micronutrient intake.  
Restriction of caffeine was set to no more than 5 cups a day, and no alcohol consumption 48 
hours prior to the visits.  Caffeine have been classified as having an ergogenic effect in low (3 
mg/kg BW), medium (5-6 mg/kg BW) and high (> 6 mg/kg BW)  doses (93, 94), and it have a 
half-life of approximately 5 to 6 hours with some individual variance (95). The participants 
got to chose if the desired one cup of coffee or tea served with the breakfast to keep caffeine 
intake at a low level. Some disadvantageous effects alcohol have on the human physiology is 
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that it influenced metabolism, myopathy of the skeletal muscle and the cardiovascular 
physiology (96). Alcohol should therefore not be consumed within 48 hours prior to the 
intervention phases.  
4.2.5 Estimated protein requirement  
Based on the available evidence, according to the NNR and Olympiatoppen Norway 
(organization that develops elite sports in Norway), a protein intake corresponding to 10–20 
E% is recommended. The NNR suggest a protein intake of 0.8 g/kg BW/day, which coincides 
to approximately 10 E% arriving from dietary protein, provided a moderate PAL of 1.6 (97). 
The participants DRI of protein was set to 1.5 g/kg BW/day based on the hours of exercise the 
participants performs each week coinciding with the recommendations of protein in relation 
to exercise from the NNR and Olympiatoppen.  
It is generally believed that there is an increased protein requirement related to exercise. There 
is an increase in demands for protein during exercise conditions that may be because on the 
increasing muscle mass, which is due to training. This also increases the breakdown of muscle 
and protein turnover in physical activity, which increases gluconeogenesis from the muscle, 
protein catabolism and a negative nitrogen balance if the energy needs are not met (98-100). 
Therefore, appropriate nutrition after exercise is important to restore homeostasis and helps 
the adaptive responses, and thus promotes the skeletal muscle reconditioning (101-103).  
 
4.3 Ghrelin and INSL5 secretion in appetite regulation and body 
weight control  
Physical activity and exercise is a common strategy in treating obesity because it increases 
energy expenditure. However, because energy expenditure increases the strength of hunger 
and is thereby driving food consumption, one can ask really how effective exercise is in 
weight regulation or weight loss. On the other hand are the evidence showing that appetite is 
suppressed and satiety is prolonged after exercise, which is further discussed below.  
 
4.3.1 Acylated ghrelin secretion in response to exercise 
Because AG is the only form of ghrelin that is able to pass the blood-brain barrier (22), it is 
assumed to be essential in appetite regulation. In addition, the previously measured 
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concentration of plasma ghrelin may disguise the vital changes in AG that arises through for 
example exercise. Previously it have been discovered that AG was suppressed whilst 
vigorously running on a treadmill (16), an increase in AG following aerobic exercise for five 
successive days (1 h/day) (104). Broom and co-workers confirmed that appetite suppression 
occurred during and after resistance and aerobic exercise, suggesting ghrelin suppresses 
appetite for exercise (15). They also suggest that the acylated ghrelin response to exercise 
may be further prolonged after higher intensity training (18).  
Not only vigorous and intense training have been shown to supress AG, but also a 120 minute 
treadmill workout with a variety of intensity (77). This bit of research is very important as 
low- to moderate exercise intensity is considered to be favourable in weight loss and weight 
regulation. Previous research have shown the effect of physical activity and exercise on AG 
secretion, and this study show a further suppression after endurance cycling when MPH 
supplementation was taken immediately after exercising. This is valuable knowledge in the 
field of weight loss especially, and a MPH supplement may be a useful tool in appetite and 
weight regulation through suppressing hunger.  
 
4.3.2 INSL5 an orexigenic hormone?  
At this point in time, there are no available data on INSL5 secretion post exercise. These 
novel results suggest that INSL5 is an anorexigenic hormone which supresses hunger and 
promotes satiety. Self-reported satiety measured supports this claim and was shown to 
stimulate satiety. INSL5 is secreted mainly from L-cells in the colon, which is the site of 
secretion of other anorexigenic hormones; GLP-1 (105), PYY (106).  
Luo and co-workers reported that INSL5 stimulated insulin secretion in vivo (51), which can 
explain the correlation found in this study. Because the site of secretion and the receptor for 
INSL5 and insulin are different. Luo proposed that INSL5 may be able to affect the secretion 
of GLP-1 through activating the RXFP4 receptor, and thereby affect insulin secretion (51). 
The mechanism of INSL5 in appetite regulation is not yet fully understood and will therefore 
need further research. This mechanism may offer a potential therapeutic target for appetite 





Chapter 5: Conclusion and future perspective 
This study have demonstrated that 20 mg marine peptide hydrolysate per kg body weight 
significantly reduced circulating acylated ghrelin after endurance cycling. There was a non-
significant change in circulating insulin-like peptide 5, insulin and glucose. This partially 
support the hypothesis that suggested that a small amount of marine peptide hydrolysate 
supplementation would affect the secretion of ghrelin after endurance cycling.  
There are definitely a greater need for more comprehensive research regarding the effect of 
marine peptides on the secretion of acylated ghrelin in response to exercise and how different 
types of exercise affect appetite regulation and meal initiation. The effect on ghrelin secretion 
after exercise are more established in the literature, and a greater reduction in ghrelin was 
found when given the marine peptide hydrolysate supplement; satiety was significantly 
suppressed after endurance cycling. This finding might represent improved therapeutic target 
for weight regulation, as physical activity and exercise is part of the recommended strategy 
for weight loss. This potential mechanism should be explored further to evaluate the potential 
in such a supplement in weight regulation.  
Insulin-like peptide 5 have a similar secretion pattern to insulin, and the correlation is very 
strong, which suggest that there may be overlapping mechanisms in regulation of both 
hormones. The marine peptide hydrolysate revealed a positive trend in circulating insulin-like 
peptide 5, however this was not significant. Based on the novel results the author propose that 
insulin-like peptide 5 increase satiety. Further exploration of this hormone and its role in 
appetite regulation is needed to establish the mechanism and its properties fully. This 
mechanism may prove to be important, not only in appetite regulation, but also in treatment of 
type 2 Diabetes.  
Due to the administrative issues, the author is not able to draw any conclusion on the 
measured satiety, however trends are reported; ghrelin supresses satiety while insulin-like 
peptide 5 promotes satiety. These results are consistent through the data sets. Satiety need to 
be further explored in conjunction with insulin-like 5 secretion to fully understand its appetite 
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Appendix 3 “Kostregistrering” from Helse Bergen, Haukeland 











































































































































Appendix 9 Reported nutritional intake compared to the Nordic nutrition 
recommendation (n = 13).  
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g
e 
o
f 
to
ta
l 
en
er
g
y
 
T
a
b
le
 1
3
 R
ep
o
rt
ed
 n
u
tr
it
io
n
a
l 
in
ta
ke
 c
o
m
p
a
re
d
 t
o
 t
h
e 
N
o
rd
ic
 n
u
tr
it
io
n
 r
ec
o
m
m
en
d
a
ti
o
n
 (
n
 =
 1
3
).
 
